-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Kidney Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Kidney Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Kidney Fibrosis Drug Details: AD-214 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Idiopathic Pulmonary Fibrosis Drug Details: AD-214 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SSGJ-611 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SSGJ-611 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SSGJ-611 in Atopic Dermatitis (Atopic Eczema) Drug Details: Monoclonal antibody...
-
Product Insights
NewHypertrophic Scars – Drugs In Development, 2024
Empower your strategies with our Hypertrophic Scars – Drugs In Development, 2024 report and make more profitable business decisions. A hypertrophic scar is a cutaneous condition characterized by deposits of excessive amounts of collagen which gives rise to a raised scar. It occurs when the body overproduces collagen, which causes the scar to be raised above the surrounding skin. Hypertrophic scars take the form of a red raised lump on the skin for lighter pigmented skin and the form of dark...
-
Product Insights
NewKidney Fibrosis – Drugs In Development, 2024
Empower your strategies with our Kidney Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors, and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea, and vomiting. The condition may be managed with...
-
Product Insights
NewInterstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or...
-
Product Insights
NewChronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewOsteoporosis – Drugs In Development, 2024
Empower your strategies with our Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, and a bone fracture that occurs much more easily than...
-
Product Insights
NewInterstitial Lung Fibrosis – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...